In the search for an ideal registry: Does the cloud have a silver lining?

Abstract

Get full access to this article

View all access options for this article.

References

Smolina

Wright

Rayner

et al.

Determinants of the decline in mortality from acute myocardial infarction in England between 2002 and 2010: Linked national database study. BMJ 2012; 344: d8059–d8059.

Yeh

Sidney

Chandra

et al.

Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010; 362: 2155–2165.

Gerber

Weston

Berardi

et al.

Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: A community study. Am J Epidemiol 2013; 178: 1272–1280.

Briffa

Hickling

Knuiman

et al.

Long-term survival after evidence based treatment of acute myocardial infarction and revascularisation: Follow-up of population based Perth MONICA cohort, 1984–2005. BMJ 2009; 338: b36–b36.

Gouya

Reichardt

Ohrenberger

et al.

Survival of patients discharged after acute myocardial infarction and evidence-based drug therapy. Eur J Epidemiol 2007; 22: 145–149.

Yan

Tan

et al.

Canadian ACS Registries Investigators. Optimal medical therapy at discharge in patients with acute coronary syndromes: Temporal changes, characteristics, and 1-year outcome. Am Heart J 2007; 154: 1108–1115.

Newby

LaPointe

Chen

et al.

Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006; 113: 203–212.

Mukherjee

Fang

Chetcuti

et al.

Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 2004; 109: 745–749.

Kirchmayer

Di Martino

Agabiti

et al.

Effect of evidence-based drug therapy on long-term outcomes in patients discharged after myocardial infarction: A nested case–control study in Italy. Pharmacoepidemiol Drug Saf 2013; 22: 649–657.

10.

Ponikowski

Voors

Anker

et al.

2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891–975.

11.

Ibanez

James

Agewall

et al.

ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39: 119–177.

12.

Gasior

Gierlotka

Pyka

et al.

Temporal trends in secondary prevention in myocardial infarction patients discharged with left ventricular systolic dysfunction in Poland. Eur J Prev Cardiol. 2018; 25: 960–969.

13.

Puymirat

Simon

Steg

et al.

Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA 2012; 308: 998–1006.

14.

Hira

Bhatt

Fonarow

et al.

Temporal trends in care and outcomes of patients receiving fibrinolytic therapy compared to primary percutaneous coronary intervention: Insights from the Get With the Guidelines Coronary Artery Disease (GWTG-CAD) registry. J Am Heart Assoc 2016; 5: e004113–e004113.

15.

Eagle

Nallamothu

Mehta

et al.

Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: We are getting better but we have got a long way to go. Eur Heart J 2008; 29: 609–617.

16.

Freisinger

Fuerstenberg

Malyar

et al.

German nationwide data on current trends and management of acute myocardial infarction: Discrepancies between trials and real-life. Eur Heart J 2014; 35: 979–988.

17.

Grey

Jackson

Wells

et al.

First and recurrent ischaemic heart disease events continue to decline in New Zealand, 2005–2015. Heart 2017; 104: 51–57.

18.

Townsend

Wilson

Bhatnagar

et al.

Cardiovascular disease in Europe: Epidemiological update 2016. Eur Heart J 2016; 37: 3232–3245.

19.

Menees

Peterson

Wang

et al.

Door-to-balloon time and mortality among patients undergoing primary PCI. N Engl J Med 2013; 369: 901–909.

20.

Nallamothu

Normand

S-LT

Wang

et al.

Relation between door-to-balloon times and mortality after primary percutaneous coronary intervention over time: A retrospective study. Lancet 2015; 385: 1114–1122.

21.

Hannan EL, Zhong Y, Jacobs AK, et al. Effect of onset-to-door time and door-to-balloon time on mortality in patients undergoing percutaneous coronary interventions for ST-segment elevation myocardial infarction. Am J Cardiol 2010; 106: 143–147.

22.

Blankenship

Scott

Skelding

et al.

Door-to-balloon times under 90 min can be routinely achieved for patients transferred for ST-segment elevation myocardial infarction percutaneous coronary intervention in a rural setting. JACC 2011; 57: 272–279.

23.

Kawecki

Gierlotka

Morawiec

et al.

Direct admission versus interhospital transfer for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2017; 10: 438–447.

24.

Keeley

Boura

Grines

. Primary angioplasty vs. intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of 23 randomised trials. Lancet 2003; 361: 13–20.

25.

Boersma

. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006; 27: 779–788.

26.

Sorajja

Gersh

Cox

et al.

Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: Analysis from the ACUITY trial. J Am Coll Cardiol 2010; 55: 1416–1424.

27.

Szummer

Wallentin

Lindhagen

et al.

Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: Experiences from the SWEDEHEART registry 1995–2014. Eur Heart J 2017; 38: 3056–3065.

28.

Rassi

Cavender

Fonarow

et al.

Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. J Am Coll Cardiol 2013; 61: 35–40.

29.

Albert

Yancy

Liang

et al.

Use of aldosterone antagonists in heart failure. JAMA 2009; 302: 1658–1665.

30.

Pitt

Bakris

Ruilope

et al.

Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 2008; 118: 1643–1650.

31.

Piepoli

Hoes

Agewall

et al.

2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol 2016; 23: NP1–NP96.

32.

Gislason

Rasmussen

Abildstrøm

et al.

Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006; 27: 1153–1158.

33.

Kirchmayer

Agabiti

Belleudi

et al.

Socio-demographic differences in adherence to evidence-based drug therapy after hospital discharge from acute myocardial infarction: A population-based cohort study in Rome, Italy. J Clin Pharm Ther 2012; 37: 37–44.

34.

Di Martino

Alagna

Cappai

et al.

Adherence to evidence-based drug therapies after myocardial infarction: Is geographic variation related to hospital of discharge or primary care providers? A cross-classified multilevel design. BMJ Open 2016; 6: e010926–e010926.

35.

Kirchmayer

Di Martino

Agabiti

et al.

Effect of evidence-based drug therapy on long-term outcomes in patients discharged after myocardial infarction: A nested case–control study in Italy. Pharmacoepidemiol Drug Saf 2013; 22: 649–657.